compounded semaglutide crackdown news november 2025 The FDA announced plans to take action against non-FDA-approved GLP-1 receptor agonists, a move that prompted telehealth company Hims & Hers to yank its new (Wegovy) weight-loss pill from the September 2, 2025: U.S. compounding

The most recently marketed Tirzepatide targets not only the GLP-1 receptors, but also the Glucose-dependent Insulinotropic Polypeptide (GIP) receptors, which have similar important functions in blood glucose regulation

Insurance Navigation Getting through insurance regulations on drugs like retatrutide may be hard

They just cant get enough of sweet, dessert-like fragrances and admit to obsessively buying up dozens of bottles of vanilla and cinnamon perfumes

Early intervention for G6PD deficiency may reduce the risk of vascular dysfunction and the incidence of CVD by correcting G6PD deficiency with small-molecule activators [12] or GSH precursors [10, 11] to prevent excessive OS

Glossary References 1